Latest Intelligence on Infectious Diseases in Switzerland

Published within

« | 1 | 2 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Basilea: promising antibiotic for MRSA

Janssen-Cilag, a subsidiary of Johnson & Johnson, has submitted a marketing authorization application to the EMEA for ceftobiprole, a new cephalosporin developed by Basilea. The drug has demonstrated potent anti-MRSA activity and in vitro activity against difficult to treat gram-negative bacteria such as multi-drug resistant Pseudomonas, potentially making it an attractive treatment option.

Published By Datamonitor
20 Jun 2007
CommentWire
CommentWire

Hepatitis A vaccine: more protection than expected

A new study suggests the hepatitis A vaccine may provide immunity for over 20 years. A new Swiss study predicts that two doses of the hepatitis A vaccine will provide immunity for over 20 years. This is longer than previously thought.<BR />

Published By Datamonitor
13 Dec 2002
CommentWire
CommentWire

Novartis/Alnylam: racing against time in flu

Novartis and Alnylam have joined to advance pandemic flu therapeutics based on RNAi through initial clinical testing and eventually regulatory approval. This focus on RNAi R&D is driven by fears that current flu vaccines and antivirals might not be sufficient to protect against the H5N1 pandemic strain and only time will tell whether an approval is granted before the impending pandemic strikes.

Published By Datamonitor
21 Feb 2006
CommentWire
CommentWire

Novartis/Chiron: a promising cash injection

Novartis has finally satisfied Chiron's board after raising its takeover bid for the firm. This is good, if unsurprising, news for Novartis, as Chiron offers the Swiss drug maker growth opportunities in vaccines and biopharmaceuticals. Indeed, despite its recent woes, Chiron should be a good buy, enabling Novartis to become a key player in the increasingly important vaccine market.

Published By Datamonitor
02 Nov 2005
CommentWire
CommentWire

Novartis: building its antiviral arsenal

Novartis has announced a $507 million licensing deal with Human Genome Sciences for Albuferon, giving Novartis rights to co-promote the hepatitis C drug candidate in the US, with exclusive marketing and promotion rights outside the US. This is the Swiss firm's latest step in its strategy to build a versatile hepatitis C portfolio and become a leading player in this high-growth market.

Published By Datamonitor
06 Jun 2006
CommentWire
CommentWire

Novartis: continuing its infectious diseases drive

Novartis has bolstered its infectious disease pipeline with two acquisitions in as many days. The Swiss firm has signed a global agreement with US-based Human Genome Sciences for hepatitis C drug candidate Albuferon and made an offer for UK-based anti-infectives developer NeuTec Pharma.

Published By Datamonitor
07 Jun 2006
CommentWire
CommentWire

Novartis: increasing presence in vaccines

Thanks to a new deal with Intercell, Novartis is set to gain access to several vaccine candidates, including those for the prevention of pneumonia in elderly and infants, and hospital-acquired Pseudomonas. After several agreements with other companies and the acquisition of Chiron in 2006, it appears Novartis is on its way to becoming a major infectious diseases player.

Published By Datamonitor
02 Jul 2007
CommentWire
CommentWire

Novartis: premium price for Chiron still to come

Chiron has snubbed Novartis' offer to acquire the remaining shares of the company that it does not already own, calling the offer "inadequate". Chiron no doubt wants to hold out for a better offer, which is a wise move since, as Novartis will be the key benefactor from the takeover, the Swiss company is likely to significantly increase its bid.

Published By Datamonitor
07 Sep 2005
CommentWire
CommentWire

Novartis: strengthening vaccines presence in the lucrative Chinese market

Novartis has completed the acquisition of an 85% stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceuticals. Faced with limited growth opportunities in the Western markets, all major vaccines players are expanding activities into growth markets due to the high incidence of vaccine-preventable diseases and increasing public and private healthcare spending.

Published By Datamonitor
24 Mar 2011
Expert View
Expert View

Roche reinforces its HIV portfolio

Recently presented data has highlighted the efficacy of Roche and Trimeris' Fuzeon plus new antiretrovirals in treatment-experienced HIV patients. The data forms part of an ongoing program of studies into the use of Fuzeon with several pipeline drugs, including the novel CCR5 inhibitors, and underlines Roche's continued commitment to the HIV market. Datamonitor's Laura Harris reports...

Published By Datamonitor
02 Aug 2005

« | 1 | 2 | » »|

No help is available.